# "Innovations at the Nanoscale: A Critical Analysis of Nanomedicine's Role in Medicine"

**A.ABHILIPSA[1] AND S.CHATTERJEE[2]**

1 DEPT. OF BIOMEDICAL ENGINEERING, MIT MANIPAL

2 DEPT. OF BIOTECHNOLOGY, MIT MANIPAL

## ABSTRACT

Nanomedicine is revolutionizing disease treatment, particularly in cancer, brain cancer, lung cancer, breast cancer, and cardiovascular diseases. With their improved blood solubility, absorption, release efficiency, and bioavailability, these cutting-edge treatments usher in a new era in drug delivery. Critical components of cancer treatment include multi-level tumor viability deterrence, ease of administration, decreased side effects, and precision targeting. Optimizing anticancer medications, reducing adverse effects, and controlling drug distribution patterns are all areas where nanoparticles regularly show promise. With an emphasis on cancer in particular, this novel strategy not only enhances the qualities of drugs but also has great potential for developing therapeutic approaches for other illnesses. The present review provides an up-to-date overview of recent advances in the field of nanomedicine and nano-based drug delivery systems and targeting mechanisms, as well as nanotherapeutics approved for oncological effects in cancer treatment. We also summarize current perspectives, benefits, and challenges in clinical translation

**Keywords:-** nanomedicine, nanoparticles, liposomes, drug delivery system, cancer, Biomarkers.

## 1.1) WHAT IS NANOMEDICINE?

The branch of medicine known as nanomedicine aims to use nanotechnology, or the manipulation and production of materials and devices that are roughly one to one hundred nanometers (nm; 1 nm = 0.0000001 cm) in size — to the anticipation of disease and to imaging, finding, checking, treatment, fix, and recovery of organic frameworks. It has revolutionized viral infection combat by utilizing nanoscale materials to enhance therapy outcomes and diagnostics. Nanomedicine is by and large connected with the creation and utilization of materials having nanoscale aspects in restorative arrangements. It is a new field that has gained attention as a location for international research and development, giving it credibility in the academic and business communities. Research in nanomedicine is supported by both public and confidential sources, with the US, the Unified Realm, Germany, and Japan being the top financial backers.

Nanomedicine could be useful to convey financially savvy treatment for old and new sicknesses, alongside diminished symptoms of medications. The majority of the organizations were hoping to benefit from expanded accentuation on nanomedicines. Nanomedicine is pushing the limits of nano-based DDS which is quickly arising with possible application to manage irresistible illnesses. Nanoparticles (NPs) play a crucial role as drug delivery vehicles because they utilize unique nanoscale properties to cross biological barriers and capitalize on the enhanced permeation and retention effect in tumors. Nanomedicine aims to identify diseases at an early stage at the cellular level. The effectiveness of active targeting in comparison to passive targeting is the subject of ongoing debate. Questions remain regarding the fate of NP-based carrier systems following administration. Although NPs may be eliminated via renal or hepatobiliary routes, their long-term fate is unknown. They might go through renal

freedom because of size or collection in assorted organs, potentially connecting with accidental off-target cells. Understanding these intricacies is urgent for streamlining nanomedicine's adequacy and guaranteeing its protected application in illness treatment and diagnostics, pushing the limits of helpful roads in the fight against viral contamination.

## 2) METHODOLOGY

### 2.1) NANOPARTICLES-

Plant-based natural products have played a significant role in medicine throughout history, with modern pharmaceuticals often derived from herbs. Around 25% of major pharmaceutical compounds on the market stem from natural resources, offering a diverse foundation for drug development. Natural compounds, with their varied molecular backgrounds, exhibit unique traits such as diverse chemical structures, macromolecular specificity, and low toxicity, making them valuable in the discovery of novel medications. Computational studies, visualizing molecular interactions, contribute to advanced drug technologies like target-based drug discovery and drug delivery.

Polymeric nanoparticles, crafted from traditional and engineered polymers, have gained attention for drug delivery due to their safety and customizable surface properties. By modifying the surface chemistry and characteristics of the polymer, these nanoparticles can be tailored for controlled drug delivery and disease-specific targeting. The small size and biodegradable nature of nanoparticles offer advantages, enabling them to navigate tissues and target specific areas effectively. Additionally, nanoparticles maintain high drug concentrations with minimal chemical reactions, preserving the pharmacological efficacy of the drug. Nano-matrices, commonly used for drug incorporation, ensure optimal delivery by varying properties and release characteristics based on the preparation method, be it through nanoparticles, nanospheres, or nanocapsules. This versatility positions nanoparticles as potent tools in pharmaceutical advancements, particularly in drug delivery and personalized medicine.

### 2.2) TARGETED DRUG DELIVERY SYSTEM

A targeted drug delivery system that can control how drugs are distributed throughout the body and reduce side effects. The fact that this strategy involves drug targeting ensures that drugs are delivered precisely where they will be most effective in the body is what makes it important. With the headway of innovation in the clinical and drug businesses, new and strong medications are grown routinely with exceptional accentuation on the medication conveyance procedures. Novel medication conveyance frameworks are being worked on to accomplish supported and better-controlled drug organization. In such frameworks, the medications are delivered utilizing both of the two significant triggers - utilization of inner upgrades or the utilization of outside improvements. The extra and intravascular set-off drug conveyance gadgets utilize different nanoparticles that discharge the medication specialist because of inward upgrades (like pH) or outer improvements. Inner setting-off components utilize the inward states of the body which encompasses the medication like, the pH conditions in the endosome of a cell, the electron partiality, and decreased possibilities of liposomes. Photograph triggerable liposomes are made utilizing photoactivated lipids which are changed to add a light-delicate substance bunch alongside the stacked medication. In cancer therapy, researchers have targeted and released magnetoelectric particles using DC and alternating magnetic fields. At the point when an attractive field is utilized as the outer trigger, the medication conveyance frameworks generally use

paramagnetic particles like iron oxide. These particles are uniquely orchestrated to be delicate and answer outside attractive fields. In addition, studies have demonstrated that weak electric fields in the strength range of approximately 1 V can trigger the release of drugs from modified conductive nano-carriers. Strong electric fields can also permeabilize cell membranes to increase drug uptake.

### 2.3) NANOMEDICINE AND DRUG DELIVERY

Nanomedicine and drug delivery systems are at the forefront of modern healthcare. These systems offer a new platform for drug delivery that can greatly increase the targeting and effectiveness of therapy. Nanotechnology has also been heralded as the cornerstone of targeted drug delivery mechanisms which will allow controlled drug release at just the right place and dose, improving patient safety and compliance and reducing side effects.




**Figure: Classes of Nanoparticles**

Targeted drug delivery involves a transport device and an active ingredient. Drug delivery vehicles under investigation vary widely and include objects known as polymeric particles, dendrimers, nanoshells, liposomes, micelles, and magnetic nanoparticles(as shown in the figure). The use of large-sized materials in drug delivery raises several challenges, including in vivo stability, poor bioavailability/solubility/absorption, and issues with target-specific delivery, in addition to the side effects of the delivered drugs. Therefore, using new drug delivery systems for targeting drugs to a specific area in the body could be an opportunity to solve these critical issues.

### 2.4) TARGETED DELIVERY OF ANTICANCER DRUGS USING NANOPARTICLES

Nano-oncology, situated at the forefront of biomedical research and engineering, harnesses nanotechnology for cutting-edge cancer diagnosis and treatment. Employing nanomaterials like dendrimers and PEGylated liposomes, this discipline enables precise drug delivery to tumor sites through both passive and active targeting methods. Nanotechnology plays a pivotal role in early cancer diagnosis, utilizing innovative strategies such




**Figure: Active and Passive targeting methods**

as biomarker imaging and interventions against multidrug resistance. Traditional cancer therapies, including chemotherapy, encounter challenges, prompting exploration into combinational approaches. Nano-oncology explores the integration of peptides, polymeric materials, and biomolecules with functional nanoparticles for diverse medical applications.

Nanotechnology's toolkit includes nanochips, nanoscale probes, and various nanoparticles, enhancing cancer detection and facilitating targeted gene delivery. The construction of medical nanodevices involves the intricate programming of nanoparticles to optimize performance. Nano-oncology holds the promise of transformative cancer therapy and diagnosis, serving as a beacon of innovation for effective, targeted, and minimally invasive solutions.

Simultaneously, nanorobots operating at the nanoscale emerge as powerful agents in enhancing treatment efficacy through minimally invasive biomedical therapies. Controlled by nanometric components, these nanorobots demonstrate an ability to recognize diverse cancer cells, delivering precise doses of anticancer drugs while minimizing harm to normal cells. Organic nanorobots, stemming from virus and bacterium DNA cells, offer a safer alternative with controlled drug release. Nanorobots present potential applications in directly targeting tumors or annihilating cancer cells, ushering in a revolutionary era of cancer treatment with targeted, low-side-effect therapies. Ongoing research remains paramount to ensure the safe, effective, and practical implementation of nanorobotics in the dynamic landscape of cancer therapy.

## 3) RESULTS

In the present landscape of medical nanotechnology, 51 products leveraging this technology are currently undergoing application in clinical settings. Notably, these nanomedicines are primarily designed for drugs with low aqueous solubility and high toxicity. These nanoformulations demonstrate the ability to mitigate toxicity while concurrently enhancing the pharmacokinetic properties of the respective drugs.




The utility of liposomes in delivering pharmaceutical agents has been established. Employing 'contact-facilitated drug delivery,' these systems involve binding or interaction with the targeted cell membrane. This process facilitates enhanced lipid-lipid exchange within the lipid monolayer of the nanoparticle, expediting the convective flux of lipophilic drugs, such as paclitaxel, to dissolve through the outer lipid membrane of the nanoparticles and reach targeted cells.

**Figure:Nanoparticle formulations greatly enhances drug delivery**

These nanosystems act as drug depots, showcasing prolonged release kinetics and extended persistence at the designated target site. While only a limited number of nanomedicines have received FDA regulation, numerous initiatives are currently underway in terms of clinical trials. This

suggests a forthcoming influx of nanotechnology-based drugs into the market. Among the nanomaterials undergoing study, 18 are directed towards chemotherapeutics, 15 are intended for antimicrobial agents, 28 have diverse applications in medical and psychological conditions, autoimmune conditions, and more, while 30 are specifically designed for nucleic acid-based therapies

### 3.1) CHALLENGES AND FUTURE

Nanomedicine's future holds promise in addressing human diseases and fortifying the body against infections, notably through advancements in immune system augmentation. The potential eradication of drug resistance is envisioned as the immune system "sentinels" swiftly disabling offending bacteria and viruses. However, widespread application faces challenges such as nanomaterial characterization, safety concerns, and regulatory issues, necessitating comprehensive and reproducible product characterization




**Figure:** **Role of nanoparticles in targeted drug delivery system**

Concerns about the toxicity of nanoparticles, commonly used, emphasise the need for targeted investigations into environmental and human health impacts. Current toxicity assessments may not fully capture the unique characteristics of nanomedicine substances, warranting the development of specific tests.

In clinical realms, challenges arise from the heterogeneity of diseases and patient-specific responses to nanomedicine, affecting successful translation into clinical trials. Rigorous evaluation of preclinical data, including factors like circulation pharmacokinetics in animal models, is vital to prevent ineffective investments in nanomedicine.

Beyond healthcare, nanomedicine plays a role in deep space exploration, offering benefits for prolonged space travel. Integrated nanomedical suites onboard spacecraft promise extreme compactness, lightness, and sophisticated medical capabilities. Innovative approaches like nanocoating implants with plant-derived pectins aim to enhance osseointegration, showcasing the diverse applications of nanomedicine.

### 4) CONCLUSIONS

Nano-delivery systems hold immense potential in overcoming challenges to efficiently target various cell types, offering a promising solution for drug resistance and enhancing drug transport through barriers like the blood-brain barrier (BBB). However, the precise characterization of molecular targets and ensuring specific effects on targeted organs remain challenging. Recent advances in modern medicine were explored, encompassing applications such as drug and gene delivery, immune system support, and health monitoring. Critical to this progress are nanoparticles, which stably load and encapsulate therapeutic cargo, safeguarding drugs from the body's harsh environment. They facilitate the delivery of water-insoluble drugs, enhancing drug transport to diseased cells and maximizing efficacy while minimizing impact on healthy cells.

Nanotechnology is reshaping vascular imaging and drug delivery methods, with nanoscale technologies poised to deliver more medical benefits in the next decade. The NIH Roadmap's 'Nanomedicine Initiatives' anticipate advancements in diagnostic and drug discovery platforms, including nanoscale cantilevers, microchip devices, and nanopore sequencing. Unlocking the full in vivo potential of nanotechnology in targeted imaging and drug delivery necessitates the development of smart nanocarriers to ensure precision and efficacy in therapeutic applications.




**Figure: Drug loading options in targeted drug delivery**

## 5) REFERENCES


1. Elisa Garbayo, et al. 'Nanomedicine and drug delivery systems in cancer and regenerative medicine.' WIREs Nanomedicine and Nanobiotechnology (2020). DOI: 10.1002/wnan.1637
2. Viseu, Ana. "nanomedicine". Encyclopedia Britannica, 7 Sep. 2023, https://www.britannica.com/science/nanomedicine. Accessed 19 December 2023.
3. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009 Jun;86(3):215-23. doi: 10.1016/j.yexmp.2008.12.004. Epub 2009 Jan 7. PMID: 19186176; PMCID: PMC3249419.
4. Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009 Jun;86(3):215-23. doi: 10.1016/j.yexmp.2008.12.004. Epub 2009 Jan 7. PMID: 19186176; PMCID: PMC3249419.
5. M. S. Shaikh, R. Donnan and R. Dubrovka, "Externally Triggered Drug Delivery Techniques Using Micro and Nanoparticles," in IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology, vol. 6, no. 3, pp. 380-390, Sept. 2022, doi: 10.1109/JERM.2022.3149685.
6. Patra, J.K., Das, G., Fraceto, L.F. et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16, 71 (2018). https://doi.org/10.1186/s12951-018-0392-8
7. H. Elayan, R. M. Shubair and N. Almoosa, "Revolutionizing the healthcare of the future through nanomedicine: Opportunities and challenges," 2016 12th International Conference on Innovations in Information Technology (IIT), Al Ain, United Arab Emirates, 2016, pp. 1-5, doi: 10.1109/INNOVATIONS.2016.7880025.
8. Yu Jin Kim et al., "Anticancer drug delivery for tumor targeting and therapy," 2009 4th IEEE International Conference on Nano/Micro Engineered and Molecular Systems, Shenzhen, 2009, pp. 919-922, doi: 10.1109/NEMS.2009.5068724.
9. P. Xu, F. Luo, W. Wei, N. Liu, J. Wei and C. Wei, "New Technology and Clinical Applications of Nanomedicine," 2007 International Symposium on Micro-NanoMechatronics and Human Science, Nagoya, Japan, 2007, pp. 519-524, doi: 10.1109/MHS.2007.4420910.